wellagain logo
My account

RGCC Cancer Treatment - Comprehensive Testing for Early Detection

Teenage oncology patient talking with doctor. Oncologist treating teen girl with cancer and provide
The inscription Cancer in colorful letters with a yellow ribbon
Young female patient with cancer looking at oncologist preparing dropper
RGCC Cancer Treatment

What Is RGCC Testing

RGCC Testing: A Breakthrough in Liquid Biopsy

Over the past decade, RGCC testing has revolutionized cancer diagnostics by providing one of the most accurate and comprehensive liquid biopsy solutions. Unlike traditional invasive procedures, RGCC testing requires only a single blood sample to detect and analyze cancer at a cellular level.

This advanced diagnostic approach applies to all types of cancer, including solid tumors, blood cancers, and sarcomas, with the exception of brain and primary tumors of the Central Nervous System (glioblastoma, astrocytoma, meningioma, etc.), which require a tissue biopsy for analysis.

Targeting the Root Cause of Cancer Recurrence

RGCC’s primary focus is on identifying and preventing the spread of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)—the key drivers of metastasis, responsible for at least 90% of all cancer-related deaths.

CTCs and CSCs contain critical information that enables them to form microcolonies, eventually leading to the development of metastatic tumors. These cells often remain undetected using conventional methods, making cancer recurrence a major challenge in oncology.

Why Blood Sample Analysis?

To combat this issue, RGCC utilizes blood samples as the most effective medium for analysis. Blood carries CTCs, providing essential data that helps:

  • Assess the risk of metastasis

  • Identify potential cancer recurrence months or even years in advance

  • Develop personalized treatment strategies based on the patient’s unique cancer profile

This cutting-edge approach ensures that patients and doctors have the most pertinent and actionable insights to stay ahead of the disease, improving both treatment outcomes and long-term survival rates.

 

Why Choose RGCC?

RGCC testing is a pioneer in liquid biopsy and is conducted in Greece under the leadership of Dr. Ioannis Papasotiriou, MD, PhD. This cutting-edge test has been perfected over the years, offering unparalleled accuracy and insight into cancer treatment and prevention.

  • Global Recognition: RGCC has set the benchmark for liquid biopsy testing, surpassing many international cancer centers in precision.

  • Personalized Treatment Insights: Identifies effective treatments tailored to the patient’s specific cancer profile.RGCC testing is a pioneer in liquid biopsy and is conducted in Greece under the leadership of Dr. Ioannis Papasotiriou, MD, PhD. This cutting-edge test has been perfected over the years, offering unparalleled accuracy and insight into cancer treatment and prevention.

    • Global Recognition: RGCC has set the benchmark for liquid biopsy testing, surpassing many international cancer centers in precision.

  • Minimal Sample Requirement: Only 15-20ml of blood is needed to analyze cancer markers, significantly reducing patient discomfort.

blood biopsy2

Who are these exams for?

Tumors With Difficulty of: Access Through Traditional Biopsy
Tumors With Difficulty of:
Access Through Traditional Biopsy
Patients Who Do Not Respond to: Conventional Treatments
Patients Who Do Not Respond to:
Conventional Treatments
Insufficient Information Obtained by: Traditional Biopsy
Insufficient Information Obtained by:
Traditional Biopsy
Patients with: Early Stage Cancer
Patients with:
Early Stage Cancer
Patients in: Generalized Advanced Stage
Patients in:
Generalized Advanced Stage
Rare or: Unknown Origin Cancers
Rare or:
Unknown Origin Cancers

Understanding Cancer Metastasis

cancer cell2

Cancer spreads through Tumor Trunk Cells, Circulating Tumor Cells (CTCs), and Cancer Stem Cells (CSCs). These cells are responsible for 90% of all cancer-related deaths, making them the primary target in cancer treatment.

  • CTCs and CSCs form microcolonies and trigger metastasis.

  • Traditional treatments often fail to target these cells, leading to recurrence.

  • RGCC testing identifies these dangerous cells, allowing for precise treatment adjustments.

Who Can Benefit from RGCC Testing?

RGCC testing is designed for:

  • Individuals looking for early cancer detection.

  • Patients seeking personalized cancer treatment options.

  • Those at risk of cancer recurrence who need regular monitoring.

Benefits, Word in 3D wooden alphabet letters isolated on background
  1. What if it was possible for you to detect cancer earlier?
  2. What if you could drastically improve your patient outcome?
  3. What if there is another way to ensure the best possible treatment for your patients?

Frequently Asked Questions

1. What is the most comprehensive RGCC test?

Onconomics Plus: Analyzes the effectiveness of cytotoxic drugs and natural biological substances. Chemosnip: Evaluates a patient’s ability to metabolize and activate drugs.

2. Can a patient include additional substances in any of their tests?

Yes, R.G.C.C. can test other natural substances requested by the patient in the Onconomics Plus or Onconomics Extracts tests. If additional tests are required for chemotherapy drugs, we may include them in the Onconomics or Onconomics Plus test.

3. How long does it take to get results?

Usually the results are available within 10 to 14 days from the exam collection date.

4. How long is it recommended to perform a monitoring / follow-up test?

From 3 to 6 months after the treatment plan.

5. Why in tissue samples are the numbers of CTCs not indicated?

Since the biopsy is already part of the tumor, it means that all the cells are cancerous. For this reason, there is no need to look for CTC populations.

6. How many cancer-specific cells are being tested for one type of cancer?

In one type of cancer for several cancer cell subpopulations, but only one has the properties tumor early (known as Cancer Stem Cells and Cancer Stem Cells ). The subset of the remainder does not actually promote the progression of the disease. Therefore, this is the population that was interested in collecting and analyzing and this subset exists to a greater extent in CTCs.

7. Is blood sample as good as a tissue sample? What are the limitations of using blood?

The main cells of interest in the analytical platform are the CTCs, which are obtained by negative selection and screening via the flow cytometer (so that we obtain only the viable CTCs from a blood sample). In cases such as Glioblastoma, cancer cells can not be detected in a blood sample because of the blood-brain barrier and we need a tissue sample in order to proceed with the test.

What can be evaluated with RGCC LIQUID BIOPSY?

SAMPLE OF YOUR BLOOD
CAN TELL YOU THE FOLLOWING:

main01

CTC’s

Circulating Tumor Cells


Circulating Tumor Cells: An Important Breakthrough in Cancer Treatment!


READ MORE ➤

CSC’s

Cancer Stem Cell:


A Little Known Truth About Cancer Recurrence


READ MORE ➤

 

Sensitivity

Chemo


Sensitivity / Resistance tests that aid in Personalization and Treatment Effectiveness


READ MORE ➤